论文部分内容阅读
目的:检测和比较卵巢癌患者在接受不同方案化疗前后HE4和CA125血清值的变化。方法:通过对医院2015年1-12月收治64例卵巢癌患者的病历调查,回顾性分析血清HE4和CA125水平值。数据使用SPSS 20.0进行统计学分析。结果:经常规化疗,卵巢癌患者血清CA125及HE4水平基本降至正常。HE4化疗前为(724.49±12.7)pmol·L~(-1),第6次后基本呈正常恢复,为(61.8±10.6)pmol·L~(-1),CA125中位数化疗前为(938.96±9.5)kU·L~(-1),第3次化疗为(32.56±9.7)kU·L~(-1),呈正常恢复。治疗中CA125和HE4相关,统计相关系数为0.985。结论:卵巢癌血清学标志物中,HE4和CA125均可作为有助于评判疗效的血清学标志物。
Objective: To detect and compare the serum levels of HE4 and CA125 in patients with ovarian cancer before and after receiving different regimens of chemotherapy. Methods: A retrospective analysis of the serum levels of HE4 and CA125 in hospital from 64 patients with ovarian cancer in January-December 2015 was conducted. Data were statistically analyzed using SPSS 20.0. Results: The levels of serum CA125 and HE4 in patients with conventional chemotherapy and ovarian cancer were basically normal. (724.49 ± 12.7) pmol·L -1 before HE4, and returned to normal after 6th (61.8 ± 10.6) pmol·L -1 .The median of CA125 was ( 938.96 ± 9.5) kU · L -1, and the third chemotherapy was (32.56 ± 9.7) kU · L -1. The treatment of CA125 and HE4 related statistical correlation coefficient of 0.985. Conclusion: Among the serological markers of ovarian cancer, HE4 and CA125 can be used as serological markers to evaluate the therapeutic effect.